Anti-tuberculosis drug-induced hepatitis in a patient far from the clinic
A 46-year-old man with newly diagnosed sputum smear-positive pulmonary tuberculosis was started on weight-based isoniazid, rifampicin, pyrazinamide and ethambutol four weeks ago. He returns with nausea, right upper quadrant discomfort, dark urine and jaundice. Total bilirubin is 4.2 mg/dL, ALT 420 U/L against a baseline of 28, alkaline phosphatase 180 U/L, and INR 1.4. He denies alcohol use, is hepatitis B and C negative, and takes no other medication. His sputum is still positive. He lives 40 km from the clinic and cannot attend frequently. The district TB officer must decide whether to stop, continue or modify treatment, and how to complete his regimen.
1. Interpret the liver results and state your immediate treatment decision.
Read the worked answer
This is anti-tuberculosis drug-induced hepatitis, most likely from isoniazid, rifampicin or pyrazinamide. The ALT is more than 10 times the upper limit of normal and the patient has symptoms plus jaundice, which meets the threshold for stopping hepatotoxic drugs. The INR of 1.4 indicates early synthetic impairment but not yet hepatic failure; he is not encephalopathic.
Stop isoniazid, rifampicin and pyrazinamide immediately. Continue ethambutol, which is not significantly hepatotoxic, and add a second effective agent so he is not left on monotherapy with a positive smear. Options include streptomycin or levofloxacin, guided by local resistance data and programme guidance.
Investigate for other causes: repeat viral hepatitis serology, ultrasound of the liver, and a careful drug and herbal history. The temporal relationship is strong, but alternative diagnoses must be excluded.
Decide the setting of care. With INR 1.4 and no encephalopathy, outpatient management with weekly review is reasonable if he can return; if not, admit him until the trend is clear. Give supportive care and avoid paracetamol and alcohol.
Do not simply reduce the doses; subtherapeutic anti-tuberculosis treatment risks treatment failure and amplification of resistance.
2. Describe a safe rechallenge or alternative regimen, and explain the reasoning behind the sequence.
Read the worked answer
Wait until the ALT has fallen to less than twice the upper limit of normal and the bilirubin is normal, then reintroduce drugs one at a time, usually starting with rifampicin because it is less often the culprit than isoniazid and is the backbone of treatment.
- Give rifampicin alone for 3-7 days and check ALT.
- If stable, add isoniazid and check again.
- Do not rechallenge with pyrazinamide, because it has a high rate of recurrence and can cause fatal hepatitis.
If the ALT rises again during sequential reintroduction, stop the most recently added drug. If a full standard regimen cannot be reconstructed, use a non-hepatotoxic regimen, for example levofloxacin, ethambutol and an injectable such as streptomycin or amikacin, continued for the duration recommended by the national programme, often 18 months or longer. The exact duration should follow current programme guidance and the patient's response.
The reasoning is that rifampicin and isoniazid are the two most effective drugs, so they are worth attempting to salvage; pyrazinamide is the least essential and the most hepatotoxic, so it is abandoned. Never leave the patient on a single active drug.
3. How would you monitor this patient given that he lives 40 km away and cannot attend often?
Read the worked answer
Design the follow-up around the constraint rather than pretending it does not exist.
- Enrol him in community-based DOTS with a treatment supporter in his village, so that adherence is observed without weekly travel.
- Give him a written danger-sign list in his own language: vomiting, yellow eyes, dark urine, confusion, bleeding, and instruct him to return immediately if any appear.
- Schedule a clinic review at 2 weeks and then monthly, with liver function tests at each visit until stable, then as clinically indicated.
- Use the phone: arrange a weekly call to the treatment supporter to check symptoms and adherence.
- Document the baseline ALT and bilirubin so that any future rise can be interpreted.
The judgement being tested is that a safe regimen is useless if it cannot be delivered. A slightly less convenient regimen with reliable supervision is better than an ideal regimen that the patient cannot access.